文献速递呼吸道感染

肺炎患者耐药病原体的区域差异及其临床意义

Regional differences in antibiotic-resistant pathogens in patients with pneumonia: Implications for clinicians.
PubMed 文献 · Respirology · 2017-08-04

本综述讨论社区起病肺炎(含社区获得性和医疗保健相关肺炎)中耐药病原体(DRPs)患病率的区域差异,范围为6%至45%。文章汇总了已报道的DRPs危险因素,并介绍用于诊断时识别DRPs患者的预测模型,强调各区域和机构应特异性评估危险因素,并提出基于DRPs风险的初始抗生素选择策略。

要点

  • 社区起病肺炎中耐药病原体患病率存在区域差异,范围为6%至45%。
  • 部分DRPs危险因素(如既往抗生素使用、既往住院)跨区域共通,但其他因素或权重可能不同。
  • 建议各区域和机构特异性评估DRPs危险因素,以指导初始抗生素选择。

核心结论

  • 社区起病肺炎中耐药病原体患病率存在区域差异,范围为6%至45%。
  • 各区域和机构应特异性评估DRPs危险因素,以指导初始抗生素选择。

研究设计与样本

  • 本文为综述,讨论社区起病肺炎(含社区获得性和医疗保健相关肺炎)患者中耐药病原体的区域差异、危险因素及预测模型。

主要发现

  • 社区起病肺炎患者中耐药病原体患病率范围为6%至45%。
  • 部分DRPs危险因素(如既往抗生素使用和既往住院)在各区域间共通,但其他因素可能不同或权重存在差异。
  • 已报道的DRPs危险因素与不恰当抗生素治疗及不良结局相关,非DRPs患者不必要的广谱抗生素使用增加死亡率。

临床怎么用

  • 医生应意识到DRPs危险因素存在区域差异,建议各区域和机构特异性评估危险因素。
  • 考虑DRPs风险,制定社区起病肺炎患者的初始抗生素选择策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibiotic resistance is of great concern for both infection control and the treatment of infectious diseases. Previous studies reported that the occurrence of drug-resistant pathogens (DRPs)-for instance, methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae-were associated with inappropriate antibiotic treatment that resulted in adverse outcomes. In addition, unnecessary use of broad-spectrum antibiotics for patients with non-DRPs increased mortality. Therefore, the assessment of risk for DRPs at diagnosis is critical to avoid patients' adverse events. In the present review, we discuss regional differences in the prevalence of DRPs, which ranged from 6% to 45%, in patients with community-onset pneumonia, including both community-acquired and healthcare-associated pneumonia. We then introduce the reported risk factors for DRPs in those patients, and present proposed prediction models for identifying patients with DRPs at diagnosis. Physicians should be aware that some of the risk factors for DRPs (e.g. prior antibiotic use and prior hospitalization) were common between regions; however, others may be different or the weighting of the risks may vary, even for the same risk factors. Therefore, a specific evaluation of risk factors for DRPs is recommended for each region and institution. Furthermore, we present a possible strategy for initial antibiotic selection in patients with community-onset pneumonia, considering DRPs risk. We also discuss future directions for the study of DRPs in community-onset, hospital-acquired and ventilator-associated pneumonia to improve the management of patients with pneumonia.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Shindo Y, Hasegawa Y. Regional differences in antibiotic-resistant pathogens in patients with pneumonia: Implications for clinicians. Respirology. 2017. PMID: 28779516. doi:10.1111/resp.13135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。